Abstract
No public abstract is available from the verified source records.
Frederik Teicher Lauridsen Kirk, Asim Ulcay, Hatice Maras, Sefa Keserci, Alba Diaz, Kaitlin Maciejewski, Regino González-Peralta, Rima Fawaz, Sanjiv Harpavat, Uyen Kim To, María-Carlota Londoño, Yanhong Deng, Thomas Damgaard Sandahl, Michael L. Schilsky, Zoe Mariñó
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The Prevalence of Wilson’s Disease: An Update
10.1002/hep.30911 · 2020
A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases
10.1002/hep.32801 · 2025
High Copper Selectively Alters Lipid Metabolism and Cell Cycle Machinery in the Mouse Model of Wilson Disease
10.1074/jbc.m607496200 · 2007
Wilson disease: histopathological correlations with treatment on follow-up liver biopsies
10.3748/wjg.v16.i12.1487 · 2010
Liver pathology in Wilson’s disease: From copper overload to cirrhosis
10.1016/j.jinorgbio.2019.01.008 · 2019
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1016/j.jhep.2023.06.003 · 2023
Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
10.1097/hep.0000000000000670 · 2024
Steatotic liver disease
10.1016/s0140-6736(24)01811-7 · 2024
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1111/apt.18059 · 2024
Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study
10.1002/hep.32635 · 2023
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
10.1016/j.jhep.2016.12.022 · 2017
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis
10.1016/j.eclinm.2022.101547 · 2022
Accuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases
2023
Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B
10.5604/16652681.1171762 · 2015
Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease
10.1016/j.dld.2009.08.002 · 2010
Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
10.5009/gnl19301 · 2021
10.1016/j.jhep.2024.04.031
10.1016/j.jhep.2024.04.031 · 2024
Hepatic steatosis in Wilson disease - Role of copper and PNPLA3 mutations
10.1016/j.jhep.2015.01.034 · 2015
Predictive value of liver enzymes in long-term prognosis of hepatic Wilson disease: results from the Wilson AEEH registry
10.1186/s13023-025-03821-1 · 2025
Application of attenuation coefficient in the assessment of hepatic involvement in children and adolescents with Wilson’s disease
10.1186/s12880-023-00979-7 · 2023
Assessment of liver involvement in Wilson’s disease with different liver echo patterns based on liver stiffness evaluated on Transient elastography and Sound Touch Viscoelastography
2025
Quantitative MR in Paediatric Patients with Wilson Disease: A Case Series Review
2022
Juvenile Wilson disease: histologic and functional studies during penicillamine therapy
10.1016/s0022-3476(75)80131-4 · 1975
Treatment of Wilson’s disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study
10.1016/j.lab.2005.01.007 · 2005
Treatment of Wilson’s disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study
10.1016/j.lab.2005.01.007 · doi-reference
Juvenile Wilson disease: histologic and functional studies during penicillamine therapy
10.1016/s0022-3476(75)80131-4 · doi-reference
Application of attenuation coefficient in the assessment of hepatic involvement in children and adolescents with Wilson’s disease
10.1186/s12880-023-00979-7 · doi-reference
Predictive value of liver enzymes in long-term prognosis of hepatic Wilson disease: results from the Wilson AEEH registry
10.1186/s13023-025-03821-1 · doi-reference
Hepatic steatosis in Wilson disease - Role of copper and PNPLA3 mutations
10.1016/j.jhep.2015.01.034 · doi-reference
10.1016/j.jhep.2024.04.031
10.1016/j.jhep.2024.04.031 · doi-reference
Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
10.5009/gnl19301 · doi-reference
Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease
10.1016/j.dld.2009.08.002 · doi-reference
Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B
10.5604/16652681.1171762 · doi-reference
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis
10.1016/j.eclinm.2022.101547 · doi-reference
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
10.1016/j.jhep.2016.12.022 · doi-reference
Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study
10.1002/hep.32635 · doi-reference
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
10.1111/apt.18059 · doi-reference
Steatotic liver disease
10.1016/s0140-6736(24)01811-7 · doi-reference
Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
10.1097/hep.0000000000000670 · doi-reference
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1016/j.jhep.2023.06.003 · doi-reference
Liver pathology in Wilson’s disease: From copper overload to cirrhosis
10.1016/j.jinorgbio.2019.01.008 · doi-reference
Wilson disease: histopathological correlations with treatment on follow-up liver biopsies
10.3748/wjg.v16.i12.1487 · doi-reference
High Copper Selectively Alters Lipid Metabolism and Cell Cycle Machinery in the Mouse Model of Wilson Disease
10.1074/jbc.m607496200 · doi-reference
A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases
10.1002/hep.32801 · doi-reference
The Prevalence of Wilson’s Disease: An Update
10.1002/hep.30911 · doi-reference